{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:01:25Z","timestamp":1792659685104,"version":"4.5.0"},"reference-count":75,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"1","license":[{"start":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T00:00:00Z","timestamp":1547510400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2019,1,15]]},"DOI":"10.1167\/iovs.18-24345","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T17:30:15Z","timestamp":1547573415000},"page":"245","source":"Crossref","is-referenced-by-count":13,"title":["Epithelial Membrane Protein-2 (EMP2) Antibody Blockade Reduces Corneal Neovascularization in an In Vivo Model"],"prefix":"10.1167","volume":"60","author":[{"given":"Michel M.","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel M.","family":"Law","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Duarte","sequence":"additional","affiliation":[{"name":"Department of Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Diaz-Aguilar","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Wadehra","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Laboratory Medicine, and Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn K.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"i1552-5783-60-1-245-b01","doi-asserted-by":"crossref","unstructured":"Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006; 443: 993\u2013997.","DOI":"10.1038\/nature05249"},{"key":"i1552-5783-60-1-245-b02","doi-asserted-by":"crossref","unstructured":"Shakiba Y, Mansouri K, Arshadi D, Rezaei N. Corneal neovascularization: molecular events and therapeutic options. Recent Pat Inflamm Allergy Drug Discov. 2009; 3: 221\u2013231.","DOI":"10.2174\/187221309789257450"},{"key":"i1552-5783-60-1-245-b03","doi-asserted-by":"crossref","unstructured":"Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004; 113: 1040\u20131050.","DOI":"10.1172\/JCI20465"},{"key":"i1552-5783-60-1-245-b04","doi-asserted-by":"crossref","unstructured":"Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001; 12: 242\u2013249.","DOI":"10.1097\/00055735-200108000-00002"},{"key":"i1552-5783-60-1-245-b05","unstructured":"Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ. 2001; 79: 214\u2013221."},{"key":"i1552-5783-60-1-245-b06","doi-asserted-by":"crossref","unstructured":"Qazi Y, Wong G, Monson B, Stringham J, Ambati BK. Corneal transparency: genesis, maintenance and dysfunction. Brain Res Bull. 2010; 81: 198\u2013210.","DOI":"10.1016\/j.brainresbull.2009.05.019"},{"key":"i1552-5783-60-1-245-b07","doi-asserted-by":"crossref","unstructured":"Chang J-H, Garg NK, Lunde E, Han K-Y, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012; 57: 415\u2013429.","DOI":"10.1016\/j.survophthal.2012.01.007"},{"key":"i1552-5783-60-1-245-b08","unstructured":"Voiculescu OB, Voinea LM, Alexandrescu C. Corneal neovascularization and biological therapy. J Med Life. 2015; 8: 444\u2013448."},{"key":"i1552-5783-60-1-245-b09","doi-asserted-by":"crossref","unstructured":"Keating AM, Jacobs DS. Anti-VEGF treatment of corneal neovascularization. Ocul Surf. 2011; 9: 227\u2013237.","DOI":"10.1016\/S1542-0124(11)70035-0"},{"key":"i1552-5783-60-1-245-b10","doi-asserted-by":"crossref","unstructured":"Avisar I, Weinberger D, Kremer I. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model. Curr Eye Res. 2010; 35: 108\u2013115.","DOI":"10.3109\/02713680903429007"},{"key":"i1552-5783-60-1-245-b11","doi-asserted-by":"crossref","unstructured":"Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008; 27: 142\u2013147.","DOI":"10.1097\/ICO.0b013e318159019f"},{"key":"i1552-5783-60-1-245-b12","doi-asserted-by":"crossref","unstructured":"Bock F, K\u00f6nig Y, Kruse F, Baier M, Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2008; 246: 281\u2013284.","DOI":"10.1007\/s00417-007-0684-4"},{"key":"i1552-5783-60-1-245-b13","doi-asserted-by":"crossref","unstructured":"Lipp M, Bucher F, Parthasarathy A, et al. Blockade of the VEGF isoforms in inflammatory corneal hemangiogenesis and lymphangiogenesis. Graefes Arch Clin Exp Ophthalmol. 2014; 252: 943\u2013949.","DOI":"10.1007\/s00417-014-2626-2"},{"key":"i1552-5783-60-1-245-b14","doi-asserted-by":"crossref","unstructured":"Yoo AR, Chung SK. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits. Cornea. 2014; 33: 1088\u20131094.","DOI":"10.1097\/ICO.0000000000000220"},{"key":"i1552-5783-60-1-245-b15","doi-asserted-by":"crossref","unstructured":"Ghasemi Falavarjani K, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013; 27: 787\u2013794.","DOI":"10.1038\/eye.2013.107"},{"key":"i1552-5783-60-1-245-b16","doi-asserted-by":"crossref","unstructured":"Fu M, Maresh EL, Helguera GF, et al. Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther. 2014; 13: 902\u2013915.","DOI":"10.1158\/1535-7163.MCT-13-0199"},{"key":"i1552-5783-60-1-245-b17","doi-asserted-by":"crossref","unstructured":"Gordon LK, Kiyohara M, Fu M, et al. EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF. Oncogene. 2013; 32: 5369\u20135376.","DOI":"10.1038\/onc.2012.622"},{"key":"i1552-5783-60-1-245-b18","doi-asserted-by":"crossref","unstructured":"Fu M, Rao R, Sudhakar D, et al. Epithelial membrane protein-2 promotes endometrial tumor formation through activation of FAK and Src. PLoS One. 2011; 6: e19945","DOI":"10.1371\/journal.pone.0019945"},{"key":"i1552-5783-60-1-245-b19","doi-asserted-by":"crossref","unstructured":"Fu M, Brewer S, Olafsen T, et al. Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments. Mol Imaging Biol. 2012; 15: 68\u201378.","DOI":"10.1007\/s11307-012-0558-y"},{"key":"i1552-5783-60-1-245-b20","doi-asserted-by":"crossref","unstructured":"Habeeb O, Goodglick L, Soslow RA, et al. Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development. Cancer. 2010; 116: 4718\u20134726.","DOI":"10.1002\/cncr.25259"},{"key":"i1552-5783-60-1-245-b21","doi-asserted-by":"crossref","unstructured":"Qin Y, Fu M, Takahashi M, et al. Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma. J Biol Chem. 2014; 289: 13974\u201313985.","DOI":"10.1074\/jbc.M113.543728"},{"key":"i1552-5783-60-1-245-b22","doi-asserted-by":"crossref","unstructured":"Qin Y, Takahashi M, Sheets K, et al. Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme. J Neurooncol. 2017; 14 (suppl 5): v1.","DOI":"10.1007\/s11060-017-2507-8"},{"key":"i1552-5783-60-1-245-b23","doi-asserted-by":"crossref","unstructured":"Chung LK, Bhatt NS, Lagman C, et al. Epithelial membrane protein 2: molecular interactions and clinical implications. J Clin Neurosci. 2017; 44: 84\u201388.","DOI":"10.1016\/j.jocn.2017.06.044"},{"key":"i1552-5783-60-1-245-b24","doi-asserted-by":"crossref","unstructured":"Williams CJ, Chu A, Jefferson WN, et al. Epithelial membrane protein 2 (EMP2) deficiency alters placental angiogenesis, mimicking features of human placental insufficiency. J Pathol. 2017; 242: 246\u2013259.","DOI":"10.1002\/path.4893"},{"key":"i1552-5783-60-1-245-b25","doi-asserted-by":"crossref","unstructured":"Wang CX, Wadehra M, Fisk BC, Goodglick L, Braun J. Epithelial membrane protein 2, a 4-transmembrane protein that suppresses B-cell lymphoma tumorigenicity. Blood. 2001; 97: 3890\u20133895.","DOI":"10.1182\/blood.V97.12.3890"},{"key":"i1552-5783-60-1-245-b26","doi-asserted-by":"crossref","unstructured":"Wadehra M, Sulur GG, Braun J, Gordon LK, Goodglick L. Epithelial membrane protein-2 is expressed in discrete anatomical regions of the eye. Exp Mol Pathol. 2003; 74: 106\u2013112.","DOI":"10.1016\/S0014-4800(03)00009-1"},{"key":"i1552-5783-60-1-245-b27","doi-asserted-by":"crossref","unstructured":"Morales SA, Mareninov S, Wadehra M, et al. FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction. Invest Ophthalmol Vis Sci. 2009; 50: 462\u2013469.","DOI":"10.1167\/iovs.07-1598"},{"key":"i1552-5783-60-1-245-b28","doi-asserted-by":"crossref","unstructured":"Morales SA, Mareninov S, Coulam P, et al. Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2). Invest Ophthalmol Vis Sci. 2009; 50: 4949\u20134956.","DOI":"10.1167\/iovs.08-3315"},{"key":"i1552-5783-60-1-245-b29","doi-asserted-by":"crossref","unstructured":"Telander DG, Morales SA, Mareninov S, Forward K, Gordon LK. Epithelial membrane protein-2 (EMP2) and experimental proliferative vitreoretinopathy (PVR). Curr Eye Res. 2011; 36: 546\u2013552.","DOI":"10.3109\/02713683.2011.561468"},{"key":"i1552-5783-60-1-245-b30","doi-asserted-by":"crossref","unstructured":"Telander DG, Yu AK, Forward KI, et al. Epithelial membrane protein-2 in human proliferative vitreoretinopathy and epiretinal membranes. Invest Ophthalmol Vis Sci. 2016; 57: 3112\u20133117.","DOI":"10.1167\/iovs.15-17791"},{"key":"i1552-5783-60-1-245-b31","doi-asserted-by":"crossref","unstructured":"Morales SA, Telander DG, Leon D, et al. Epithelial membrane protein 2 controls VEGF expression in ARPE-19 cells. Invest Ophthalmol Vis Sci. 2013; 54: 2367\u20132372.","DOI":"10.1167\/iovs.12-11013"},{"key":"i1552-5783-60-1-245-b32","doi-asserted-by":"crossref","unstructured":"Anderson C, Zhou Q, Wang S. An alkali-burn injury model of corneal neovascularization in the mouse. J Vis Exp. 2014; e51159\u2013e51159.","DOI":"10.3791\/51159"},{"key":"i1552-5783-60-1-245-b33","doi-asserted-by":"crossref","unstructured":"Longair MH, Baker DA, Armstrong JD. Simple neurite tracer: open source software for reconstruction, visualization and analysis of neuronal processes. Bioinformatics. 2011; 27: 2453\u20132454.","DOI":"10.1093\/bioinformatics\/btr390"},{"key":"i1552-5783-60-1-245-b34","doi-asserted-by":"crossref","unstructured":"G\u00fcell JL, Husseiny El MA, Manero F, Gris O, Elies D. Historical review and update of surgical treatment for corneal endothelial diseases. Ophthalmol Ther. 2014; 3: 1\u201315.","DOI":"10.1007\/s40123-014-0022-y"},{"key":"i1552-5783-60-1-245-b35","doi-asserted-by":"crossref","unstructured":"Holyoake TL, Alcorn MJ, Franklin IM. The CD34 antigen: potential clinical advantages of CD34 selection. Clin Oncol (R Coll Radiol) 1996; 8: 214\u2013221.","DOI":"10.1016\/S0936-6555(05)80655-7"},{"key":"i1552-5783-60-1-245-b36","doi-asserted-by":"crossref","unstructured":"Arbab AS. CD34+\/AC133+ Endothelial progenitor cells as imaging probes for neovascularization of tumors. In: Stem Cells and Cancer Stem Cells, Volume 9: Therapeutic Applications in Disease and Injury. Dordrecht: Springer; 2013: 203\u2013217.","DOI":"10.1007\/978-94-007-5645-8_20"},{"key":"i1552-5783-60-1-245-b37","doi-asserted-by":"crossref","unstructured":"Wadehra M, Iyer R, Goodglick L, Braun J. The tetraspan protein epithelial membrane protein-2 interacts with \u00df1 integrins and regulates adhesion. J Biol Chem. 2002; 277: 41094\u201341100.","DOI":"10.1074\/jbc.M206868200"},{"key":"i1552-5783-60-1-245-b38","doi-asserted-by":"crossref","unstructured":"Forbes A, Wadehra M, Mareninov S, et al. The tetraspan protein EMP2 regulates expression of caveolin-1. J Biol Chem. 2007; 282: 26542\u201326551.","DOI":"10.1074\/jbc.M702117200"},{"key":"i1552-5783-60-1-245-b39","doi-asserted-by":"crossref","unstructured":"Wadehra M, Su H, Gordon LK, Goodglick L, Braun J. The tetraspan protein EMP2 increases surface expression of class I major histocompatibility complex proteins and susceptibility to CTL-mediated cell death. Clin Immunol. 2003; 107: 129\u2013136.","DOI":"10.1016\/S1521-6616(03)00048-2"},{"key":"i1552-5783-60-1-245-b40","doi-asserted-by":"crossref","unstructured":"Koehne P, Willam C, Strauss E, Schindler R, Eckardt KU, B\u00fchrer C. Lack of hypoxic stimulation of VEGF secretion from neutrophils and platelets. Am J Physiol Heart Circ Physiol. 2000; 279: H817\u2013H824","DOI":"10.1152\/ajpheart.2000.279.2.H817"},{"key":"i1552-5783-60-1-245-b41","unstructured":"Schlegel C, Paul P, Lee S, et al. Protein kinase C regulates bombesin-induced rapid VEGF secretion in neuroblastoma cells. Anticancer Res. 2012; 32: 4691\u20134696."},{"key":"i1552-5783-60-1-245-b42","unstructured":"Klettner A, Westhues D, Lassen J, Bartsch S, Roider J. Regulation of constitutive vascular endothelial growth factor secretion in retinal pigment epithelium\/choroid organ cultures: p38, nuclear factor ?B, and the vascular endothelial growth factor receptor-2\/phosphatidylinositol 3 kinase pathway. Mol Vis. 2013; 19: 281\u2013291."},{"key":"i1552-5783-60-1-245-b43","unstructured":"Puddu A, Sanguineti R, Durante A, Nicol\u00f2 M, Viviani GL. Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization. Mol Vis. 2012; 18: 2509\u20132517."},{"key":"i1552-5783-60-1-245-b44","doi-asserted-by":"crossref","unstructured":"Kommineni VK, Nagineni CN, William A, Detrick B, Hooks JJ. IFN-gamma acts as anti-angiogenic cytokine in the human cornea by regulating the expression of VEGF-A and sVEGF-R1. Biochem Biophys Res Commun. 2008; 374: 479\u2013484.","DOI":"10.1016\/j.bbrc.2008.07.042"},{"key":"i1552-5783-60-1-245-b45","doi-asserted-by":"crossref","unstructured":"Kim LA, D'Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol. 2012; 181: 376\u2013379.","DOI":"10.1016\/j.ajpath.2012.06.006"},{"key":"i1552-5783-60-1-245-b46","doi-asserted-by":"crossref","unstructured":"Kong D-H, Kim MR, Jang JH, Na H-J, Lee S. A review of anti-angiogenic targets for monoclonal antibody cancer therapy. Int J Mol Sci. 2017; 18: 1786.","DOI":"10.3390\/ijms18081786"},{"key":"i1552-5783-60-1-245-b47","doi-asserted-by":"crossref","unstructured":"Rejdak R. New drug VEGF Trap-Eye \u2013 Eylea in the treatment of age-related macular degeneration, and macular edema in central retinal vein occlusion and diabetic retinopathy. Pharmacol Rep. 2013; 65: 26.","DOI":"10.1016\/S1734-1140(13)71295-7"},{"key":"i1552-5783-60-1-245-b48","doi-asserted-by":"crossref","unstructured":"Aparicio LMA, Fernandez IP, Cassinello J. Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy. Clin Transl Oncol. 2017; 5: 257\u2013258.","DOI":"10.1007\/s12094-017-1657-7"},{"key":"i1552-5783-60-1-245-b49","doi-asserted-by":"crossref","unstructured":"Wong HH, Eisen T. First-generation tyrosine kinase inhibitors: clinical results. In: Renal Cell Carcinoma. New York, NY: Springer; 2015: 177\u2013205.","DOI":"10.1007\/978-1-4939-1622-1_8"},{"key":"i1552-5783-60-1-245-b50","doi-asserted-by":"crossref","unstructured":"Al-Abd AM, Alamoudi AJ, Abdel-Naim AB, Neamatallah TA, Ashour OM. Anti-angiogenic agents for the treatment of solid tumors: potential pathways, therapy and current strategies \u2013 a review. J Adv Res. 2017; 8: 591\u2013605.","DOI":"10.1016\/j.jare.2017.06.006"},{"key":"i1552-5783-60-1-245-b51","doi-asserted-by":"crossref","unstructured":"Pozarowska D, Pozarowski P. The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. Cent Eur J Immunol. 2016; 3: 311\u2013316.","DOI":"10.5114\/ceji.2016.63132"},{"key":"i1552-5783-60-1-245-b52","doi-asserted-by":"crossref","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355: 1419\u20131431.","DOI":"10.1056\/NEJMoa054481"},{"key":"i1552-5783-60-1-245-b53","doi-asserted-by":"crossref","unstructured":"Folk JC, Stone EM. Ranibizumab therapy for neovascular age-related macular degeneration. N Engl J Med. 2010; 363: 1648\u20131655.","DOI":"10.1056\/NEJMct1000495"},{"key":"i1552-5783-60-1-245-b54","doi-asserted-by":"crossref","unstructured":"Li X, Zarbin MA, Bhagat N. Anti-vascular endothelial growth factor injections: the new standard of care in proliferative diabetic retinopathy? Dev Ophthalmol. 2017; 60: 131\u2013142.","DOI":"10.1159\/000459699"},{"key":"i1552-5783-60-1-245-b55","doi-asserted-by":"crossref","unstructured":"Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010; 117: 2146\u20132151.","DOI":"10.1016\/j.ophtha.2010.08.016"},{"key":"i1552-5783-60-1-245-b56","doi-asserted-by":"crossref","unstructured":"Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Virgili G, ed. Cochrane Database Syst Rev. 2017; 6: CD007419.","DOI":"10.1002\/14651858.CD007419.pub5"},{"key":"i1552-5783-60-1-245-b57","doi-asserted-by":"crossref","unstructured":"Simha A, Braganza A, Abraham L, Samuel P, Lindsley K. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2013; 66: CD007920.","DOI":"10.1002\/14651858.CD007920.pub2"},{"key":"i1552-5783-60-1-245-b58","doi-asserted-by":"crossref","unstructured":"Thach AB, Yau L, Hoang C, Tuomi L. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology. 2014; 121: 1059\u20131066.","DOI":"10.1016\/j.ophtha.2013.11.022"},{"key":"i1552-5783-60-1-245-b59","doi-asserted-by":"crossref","unstructured":"Varma R, Bressler NM, Su\u00f1er I, et al. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology. 2012; 119: 2108\u20132118.","DOI":"10.1016\/j.ophtha.2012.05.017"},{"key":"i1552-5783-60-1-245-b60","doi-asserted-by":"crossref","unstructured":"Braithwaite T, Nanji AA, Lindsley K, Greenberg PB. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev. 2014; 119: CD007325.","DOI":"10.1002\/14651858.CD007325.pub3"},{"key":"i1552-5783-60-1-245-b61","doi-asserted-by":"crossref","unstructured":"Altintas AGK, Arifoglu HB, Tutar E, Koklu G, Ozcan PY. Effect on anterior chamber bevacizumab injection combined with seton implantation in treatment of rubeosis iridis in neovascular glaucoma. Cutan Ocul Toxicol. 2012; 31: 124\u2013127.","DOI":"10.3109\/15569527.2011.621917"},{"key":"i1552-5783-60-1-245-b62","doi-asserted-by":"crossref","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011; 364: 603\u2013615.","DOI":"10.1056\/NEJMoa1007374"},{"key":"i1552-5783-60-1-245-b63","doi-asserted-by":"crossref","unstructured":"Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr. 2009; 21: 182\u2013187.","DOI":"10.1097\/MOP.0b013e32832925f9"},{"key":"i1552-5783-60-1-245-b64","doi-asserted-by":"crossref","unstructured":"Reynolds JD. Bevacizumab for retinopathy of prematurity. N Engl J Med. 2011; 364: 677\u2013678.","DOI":"10.1056\/NEJMe1100248"},{"key":"i1552-5783-60-1-245-b65","doi-asserted-by":"crossref","unstructured":"Stockman JA III. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. Yearbook of Pediatrics. 2012; 2012: 511\u2013513.","DOI":"10.1016\/j.yped.2011.06.060"},{"key":"i1552-5783-60-1-245-b66","doi-asserted-by":"crossref","unstructured":"Ziemssen F, Sobolewska B, Deissler H, Deissler H. Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues. Expert Opin Drug Saf. 2016; 15: 75\u201387.","DOI":"10.1517\/14740338.2016.1121232"},{"key":"i1552-5783-60-1-245-b67","doi-asserted-by":"crossref","unstructured":"Di Lisi D, Madonna R, Zito C, et al. Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. Int J Cardiol. 2017; 227: 11\u201317.","DOI":"10.1016\/j.ijcard.2016.11.174"},{"key":"i1552-5783-60-1-245-b68","doi-asserted-by":"crossref","unstructured":"Ueta T, Noda Y, Toyama T, Yamaguchi T, Amano S. Systemic vascular safety of ranibizumab for age-related macular degeneration. Ophthalmology. 2014; 121: 2193\u20132203.e2197.","DOI":"10.1016\/j.ophtha.2014.05.022"},{"key":"i1552-5783-60-1-245-b69","doi-asserted-by":"crossref","unstructured":"Scott LJ, Chakravarthy U, Reeves BC, Rogers CA. Systemic safety of anti-VEGF drugs: a commentary. Expert Opin Drug Saf. 2015; 14: 379\u2013388.","DOI":"10.1517\/14740338.2015.991712"},{"key":"i1552-5783-60-1-245-b70","doi-asserted-by":"crossref","unstructured":"Thulliez M, Angoulvant D, Le Lez ML, et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies. JAMA Ophthalmol. 2014; 132: 1317\u20131326.","DOI":"10.1001\/jamaophthalmol.2014.2333"},{"key":"i1552-5783-60-1-245-b71","unstructured":"Fasih U, Shaikh N, Rahman A, Sultan S, Fehmi MS, Shaikh A. A one-year follow-up study of ocular and systemic complications of intravitreal injection of bevacizumab (Avastin). J Pak Med Assoc. 2013; 63: 707\u2013710."},{"key":"i1552-5783-60-1-245-b72","doi-asserted-by":"crossref","unstructured":"Penha FM, Rodrigues EB, Furlani BA, Dib E, Melo GB, Farah ME. Toxicological considerations for intravitreal drugs. Expert Opin Drug Metab Toxicol. 2011; 7: 1021\u20131034.","DOI":"10.1517\/17425255.2011.585970"},{"key":"i1552-5783-60-1-245-b73","doi-asserted-by":"crossref","unstructured":"Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011; 95: 1111\u20131114.","DOI":"10.1136\/bjo.2010.180729"},{"key":"i1552-5783-60-1-245-b74","doi-asserted-by":"crossref","unstructured":"Horsley MB, Mandava N, Maycotte MA, Kahook MY. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2010; 150: 558\u2013561.e1.","DOI":"10.1016\/j.ajo.2010.04.029"},{"key":"i1552-5783-60-1-245-b75","doi-asserted-by":"crossref","unstructured":"Giet M, Henkel C, Schuchardt M, Tolle M. Anti-VEGF drugs in eye diseases: local therapy with potential systemic effects. Curr Pharm Des. 2015; 21: 3548\u20133556.","DOI":"10.2174\/1381612821666150225120314"}],"container-title":["Investigative Opthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?articleid=2722583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:31:05Z","timestamp":1791927065000},"score":1,"resource":{"primary":{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?doi=10.1167\/iovs.18-24345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,15]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,2]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.18-24345","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,15]]}}}